anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 228,571-228,600
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

228,571-228,600 of 303,780

filter-aware
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
16
Data presented as mean +/- S.E. of mean; N=7 patients.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
18
The slide provides clinical safety data for the KT-474 drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
19
The slide outlines the status of a partnership with Sanofi and clinical trial timelines.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
21
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
23
Includes PK/PD data and efficacy metrics in multiple T-cell lymphoma models.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
24
Includes box plots for gene expression and a tumor volume growth curve over time.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
25
The slide uses a process flow diagram to illustrate the transition from dose escalation (DL1-DLx) to expansion cohorts for specific indications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
26
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
27
Data cut-off: 18 October 2023. Includes breakdown by age, sex, ECOG status, prior therapy, and tumor type.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
28
Clinical trial safety data summary.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
29
The table tracks clinical trial outcomes (PR: Partial Response, SD: Stable Disease, PD: Progressive Disease) for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
30
Includes both tabular summary of dose-level degradation and visual histology/bar chart evidence of tumor reduction.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
31
Includes longitudinal line charts for blood mRNA levels and a bar chart/enrichment plot for tumor response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a split-layout: left side for clinical data results, right side for strategic opportunity/implications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
33
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
35
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
36
Comparison of protein levels and tumor volume over time across multiple dosing regimens.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
37
The slide uses a standard clinical trial dose-escalation diagram and a demographic table.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
38
The slide uses a biological mechanism diagram on the left and clinical data (table and line chart) on the right to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
39
The chart is a swimmer plot, a standard tool in oncology clinical trials to visualize duration of response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
40
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
41
The slide uses a split-layout comparing technical mechanism/data (left) with strategic opportunity (right).Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
42
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
44
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
45
The table displays patient counts and percentages for specific adverse events categorized by dose level (DL1-DL5) and overall.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Includes both a summary table of response categories and a swimmer plot for treatment duration.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
01
Slide 1
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations 1 hit